三重激动剂 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Culver's soon shifted its attention to developing markets beyond the Midwest, and opened the first franchise outside the region in Texas in February 1998. The current franchising strategy is one of strategic expansion. The chain expanded into Colorado Springs, Colorado and Cheyenne, Wyoming in 2005, followed by an opening in Bowling Green, Kentucky in July 2006. Locations traditionally had a 120-seat format through much of Culver's expansion. The Metro-98 prototype was developed in 2006 and first constructed in Fort Dodge, Iowa. While the new layout has less seating to offer guests, it also reduced the amount of land needed for construction by around 20%. The company expanded to the Phoenix metropolitan area in 2008. The first franchise in Utah opened in Midvale in 2011, when a couple from Wisconsin relocated there. They signed a development agreement for four locations in the southern half of Salt Lake County. By the end of 2011, 445 Culver's restaurants were open in 19 states. They opened in South Carolina in 2012; Florida, Georgia, and Tennessee in 2014; and North Carolina in 2015. A location was announced for Alabama in June 2018, and expansion continued into Arkansas in January 2022. In February 2026, Culver's announced plans to enter the Virginia market, starting with their first location in the Richmond area.
== In tomatoes == Some, such as the California Poison Control Center, have claimed that unripe tomatoes and tomato leaves contain solanine. However, Mendel Friedman of the United States Department of Agriculture contradicts this claim, stating that tomatine, a relatively benign alkaloid, is the tomato alkaloid while solanine is found in potatoes. Food science writer Harold McGee has found scant evidence for tomato toxicity in the medical and veterinary literature.
However, others have pointed out that C-peptides are produced in hypoglycaemic attacks caused by insulin produced naturally in the body, and these were not detected in any of the blood tests of the victims, indicating that the insulin had been introduced to their bodies externally and artificially. Norris lost an appeal against his conviction in 2009. In February 2021, the Criminal Cases Review Commission referred the case back to the Court of Appeal; this second appeal, heard in 2025, was also unsuccessful. Norris is believed to have been inspired by Jessie McTavish, a fellow Scottish nurse who was convicted of murdering a patient with insulin in 1974 before having her conviction quashed in 1975. The incident had happened at Ruchill Hospital in Glasgow, less than a mile from where Norris grew up. Shortly before he registered as a nurse, he had learned about McTavish.
Sources: en.wikipedia.org
== Atomic spectroscopy == Electrons exist in energy levels (i.e. atomic orbitals) within an atom. Atomic orbitals are quantized, meaning they exist as defined values instead of being continuous (see: atomic orbitals). Electrons may move between orbitals, but in doing so they must absorb or emit energy equal to the energy difference between their atom's specific quantized orbital energy levels. In optical spectroscopy, energy absorbed to move an electron to a higher energy level (higher orbital) and/or the energy emitted as the electron moves to a lower energy level is absorbed or emitted in the form of photons (light particles). Because each element has a unique number of electrons, an atom will absorb/release energy in a pattern unique to its elemental identity (e.g. Ca, Na, etc.) and thus will absorb/emit photons in a correspondingly unique pattern. The type of atoms present in a sample, or the amount of atoms present in a sample can be deduced from measuring these changes in light wavelength and light intensity. Atomic spectroscopy is further divided into atomic absorption spectroscopy and atomic emission spectroscopy. In atomic absorption spectroscopy, light of a predetermined wavelength is passed through a collection of atoms. If the wavelength of the source light has energy corresponding to the energy difference between two energy levels in the atoms, a portion of the light will be absorbed. The difference between the intensity of the light emitted from the source (e.g., lamp) and the light collected by the detector yields an absorbance value.
Two developments dominated the decade that followed: the increasingly apparent crumbling of the Soviet Union's economic and political structures, and the patchwork attempts at reforms to reverse that process. Kenneth S. Deffeyes argued in Beyond Oil that the Reagan administration encouraged Saudi Arabia to lower the price of oil to the point where the Soviets could not make a profit selling their oil, and resulted in the depletion of the country's hard currency reserves. Brezhnev's next two successors, transitional figures with deep roots in his tradition, did not last long. Yuri Andropov was 68 years old and Konstantin Chernenko 72 when they assumed power; both died in less than two years. In an attempt to avoid a third short-lived leader, in 1985, the Soviets turned to the next generation and selected Mikhail Gorbachev. He made significant changes in the economy and party leadership, called perestroika. His policy of glasnost freed public access to information after decades of heavy government censorship. Gorbachev also moved to end the Cold War. In 1988, the USSR abandoned its war in Afghanistan and began to withdraw its forces. In the following year, Gorbachev refused to interfere in the internal affairs of the Soviet satellite states, which paved the way for the Revolutions of 1989. In particular, the standstill of the Soviet Union at the Pan-European Picnic in August 1989 then set a peaceful chain reaction in motion, at the end of which the Eastern Bloc collapsed.
=== Worms === The microscopic soil-dwelling nematode roundworms Panagrolaimus detritophagus and Plectus parvus are the only eukaryotic organisms that have been proven to be viable after cryopreservation for many years (30,000 to 40,000 years). In this case, the preservation was natural rather than artificial, due to permafrost. They came alive when warmed up.
Sources: en.wikipedia.org
=== SELEX === Conventional (up to 1016 different oligonucleotides) existing molecule library serves as a starting point for the subsequent SELEX process. Selection, separation, and amplification using the mirror image of the target molecule is performed.
This is a list of radioactive nuclides (sometimes also called isotopes), ordered by half-life from shortest to longest, in seconds, minutes, hours, days and years. Current methods make it difficult to measure half-lives between approximately 10−19 and 10−10 seconds.
=== Components of the endocrine reproductive system === The arcuate nucleus of the hypothalamus is the driver of the reproductive system. It has neurons which generate and release pulses of GnRH into the portal venous system of the pituitary gland. The arcuate nucleus is affected and controlled by neuronal input from other areas of the brain and hormonal input from the gonads, adipose tissue and a variety of other systems. The pituitary gland responds to the pulsed GnRH signals by releasing LH and FSH into the blood of the general circulation, also in a pulsatile pattern. The gonads (testes and ovaries) respond to rising levels of LH and FSH by producing the steroid sex hormones, testosterone and estrogen. The adrenal glands are a second source for steroid hormones. Adrenal maturation, termed adrenarche, typically precedes gonadarche in mid-childhood.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.